Stay updated with breaking news from Efficacy Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.
Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice.
– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ --...
A brief discussion on the respective roles of EZH2- and PI3K-targeted therapies in patients with relapsed/refractory follicular lymphoma.
A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.